Clinical Trial Update: A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus [Phase 3]

View source ↗

Summary

A 52-week Phase 3 clinical trial is evaluating the efficacy and safety of delgocitinib cream in adults with lichen sclerosus; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lichen Sclerosus

Drugs mentioned

• Delgocitinib Cream (delgocitinib)

Snippet

Sponsor: LEO Pharma | Conditions: Lichen Sclerosus | Phase 3 | Status: NOT_YET_RECRUITING